In the press release “Nanochon Receives Regulatory Approval from Panama’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft,” Nanochon announced a new advancement in its efforts to begin human clinical trials of its 3D printed knee implant, Chondrograft™. A U.S.-based medical device startup co-founded by GW Engineering alumnus Ben Holmes, Ph.D. ‘16, Nanochon recently received regulatory approval from Panama’s Ministry of Health to initiate its First-in-Human clinical study in Panama.
Here is an excerpt from the article: “This approval marks a significant milestone for Nanochon and validates the momentum behind our clinical development program,” said Holmes. “Panama’s streamlined regulatory environment and strong clinical ecosystem provide an excellent foundation for advancing orthopedic technologies like Chondrograft™ into human studies.”
Read the full article on PR Newswire. For more coverage, check out TipRanks, Business Wire, and Orthopedics This Week, and read about how the first-in-human trial is developing in the follow-up article by Morning Star.